Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.56 |
| ▸ | TNF | P01375 | 3/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824463 | 1.00 | TLR2 (0.56) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL8223034 | 1.00 | TLR2 (0.56) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL30323573 | 0.96 | TLR2 (0.61) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL14049640 | 0.90 | TLR2 (0.63) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL13464732 | 0.90 | TLR2 (0.63) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL31126369 | 0.90 | TLR2 (0.63) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL29613683 | 0.89 | CASP3 (0.55) | TLR2TNFMDM4TP53CASP3 | |
| SCHEMBL30656568 | 0.89 | MDM4 (0.59) | TNFMDM4TP53CASP3MDM2 | |
| SCHEMBL18699448 | 0.89 | TLR2 (0.49) | TLR2TNFCASP3 | |
| SCHEMBL6190530 | 0.87 | CASP3 (0.57) | TLR2TNFMDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185908-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | Pfizer Inc (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030791-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | disclosed |
| US-20120264685-A1 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | CADILA HEALTHCARE LIMITED (IN) | 2012-10-18 | — | — | US | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264685-A1 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | GIPR, GLP1R, DPP4 | TLR2 1621/4885TNF 2326/4885MDM4 3879/4885 |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | TLR2 1355/4885TNF 2511/4885MDM4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.